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Summary
A 20-year-old man with an 8-year history of progressive enlargement of his hands and feet, coarsening facial features, 
painful joints and thickened, oily skin was referred for investigation of acromegaly. On examination, the subject was 
of normal height and weight. He had markedly increased skin thickness around the forehead, eyelids and scalp with 
redundant skin folds. Bilateral painful knee swelling was accompanied by enlargement of the extremities, and his 
fingers were markedly clubbed. Routine hematological, biochemical and hormonal blood tests, including GH and IGF-1 
were normal. The clinical picture suggested primary hypertrophic osteoarthropathy (PHOA) rather than acromegaly 
and radiological studies were supportive of this, demonstrating increased subperiosteal bone formation and increased 
bone density and cortical thickening. There was widespread joint disease, with narrowing of joint spaces, whereas the 
knees demonstrated effusions and calcification. A skull X-ray revealed calvarial hyperostosis and a normal sellar outline. 
Family history was negative. Genetic studies were performed on peripheral blood leukocyte DNA for mutations in the 
two genes associated with PHOA, 15-hydroxyprostaglandin dehydrogenase (HPGD; OMIM: 601688) and solute carrier 
organic anion transporter family member 2A1 (SLCO2A1; OMIM: 601460). The sequence of HPGD was normal, whereas 
the subject was homozygous for a novel pathological variant in SLCO2A1, c.830delT, that predicted a frameshift and early 
protein truncation (p.Phe277Serfs*8). PHOA, also known as pachydermoperiostosis, is a rare entity caused by abnormal 
prostaglandin E2 metabolism, and both HPGD and SLCO2A1 are necessary for normal prostaglandin E2 handling. High 
prostaglandin levels lead to bone formation and resorption and connective tissue inflammation causing arthropathy, in 
addition to soft tissue swelling.
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•	 The differential diagnosis of enlarged extremities, coarsened facial features, skin changes and increased sweating 
in suspected acromegaly is quite limited and primary hypertrophic osteoarthropathy (PHOA) is one of the few 
conditions that can mimic acromegaly at presentation.
•	 PHOA is not associated with abnormalities in GH and IGF-1 secretion and can be readily differentiated from 
acromegaly by hormonal testing.
•	 Clubbing in the setting of diffuse enlargement of joints and extremities in addition to skin changes should alert 
the physician to the possibility of PHOA, as clubbing is not a usual feature of acromegaly. Underlying causes of 
secondary hypertrophic osteoarthroapthy (e.g. bronchial neoplasia) should be considered.
•	 PHOA is a very rare condition caused by abnormalities in prostaglandin metabolism and has two known genetic 
causes (HPGD and SLCO2A1 mutations).
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The current case illustrates well the potential for PHOA to 
present as a queried case of acromegaly. The presentation 
at a community clinic with a gradual onset of increased 
size of hands and feet, facial coarsening, increased 
sweating and seborrhea led to a referral to a specialist 
endocrinology department to rule out acromegaly. The 
differential diagnosis of acromegaly is quite limited, so it 
is important to be aware of PHOA as a rare differential. 
The young male patient had the full clinical picture of 
PHOA (pachyderma, clubbing and periostosis), and he 
was homozygous for a novel pathological change in the 
SLCO2A1 gene. This mutation has not been reported 
previously and is only the second SLCO2A1 mutation 
reported in Latin America.
Case presentation
A 20-year-old Venezuelan male patient was referred for 
investigation of a possible diagnosis of acromegaly. He was 
of normal height (170 cm) and weight (62 kg). Beginning 
at the age of 12 years, he had progressive enlargement of 
his hands and feet and painful swelling of his knees and 
ankles. There was no family history of similar complaints. 
On examination, the patient had coarse facial features, 
thickened eyelids and partial blepharoptosis. Extensive 
dark, oily redundant skin folds were present on the 
forehead and scalp with prominent grooves consistent 
with cutis verticis gyrata (Fig. 1). His hands and feet were 
swollen, and his hands were markedly clubbed (Fig. 2). His 
main clinical complaint was knee pain, due to extensive 
swelling and effusions bilaterally.
Investigation
Routine hematological and biochemical blood tests were 
within normal limits. His GH, IGF-1 and thyroid function 
tests were also normal, indicating that acromegaly was 
not the cause of his clinical features. Urinary testing for 
prostaglandins and metabolites was not available.
Radiologic studies of his limbs demonstrated 
subperiostial bone formation with bone density and 
cortical thickening (Fig.  3). Hand radiographs revealed 
similar subperiosteal bone formation, phalangeal 
thickening and decreased joint spaces at the carpus (Fig. 4). 
The knees showed bony excrescences in the patellae and 
involvement of the proximal tibia and distal femur with 
calcification and signs of effusion. A lateral radiograph of 
the skull demonstrated a normal sella with hyperostosis 
of the skull bones (Fig.  5). The patient had no signs of 
pulmonary disease, and PHOA was diagnosed. Given the 
known genetic causes of PHOA, the patient underwent 
sequencing of the hydroxyprostaglandin dehydrogenase 
Figure 1
Facial changes in primary hypertrophic osteoarthropathy demonstrating 
thickened oily skin and excessive folding of the skin of the forehead 
(cutis verticis gyrata).
•	 SLCO2A1 gene mutations lead usually to autosomal recessive PHOA; fewer than 50 SLCO2A1 mutations have been 
described to date and the current case is only the second in a Hispanic patient.
•	 Treatment of primary hypertrophic osteoarthropathy is focused on the management of joint pain usually in the 
form of non-steroidal anti-inflammatory drug therapy.
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(HPGD) and solute carrier organic anion transporter 
family member 2A1 (SLCO2A1) genes.
Treatment
Once a diagnosis of acromegaly had been discounted and 
the multifocal bone and joint disease diagnosed, he was 
treated with oral bisphosphonate therapy and regular 
non-steroidal anti-inflammatory drugs to reduce pain and 
inflammation.
Figure 2
Digital clubbing in primary hypertropic osteoarthropathy.
Figure 3
Periosteal new bone formation (periostosis) in the tibia and radius (white 
arrows) with associated cortical thickening.
Figure 4
Typical radiological features of the distal upper limb and hands of a 
patient with primary hypertrophic osteoarthropathy showing increased 
density of the carpal, metacarpal and phalangeal bones with reduction in 
joint spaces and soft tissue swelling.
Figure 5
Lateral radiograph of the cranium showing a normal sella turcica (black 
arrow) and cranial hyperostosis (white arrow).
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Pain and joint swelling improved substantially after the 
initiation of non-steroidal anti-inflammatory therapy and 
bisphosphonate treatment. After two years of follow-up, 
the joint swelling and discomfort remains controlled, 
but there was no improvement in the skin disorder 
and established bone disease. The subject is scheduled 
for plastic surgery for reduction of facial skin folds and 
blepharoplasty for relief of his blepharoptosis.
Discussion
PHOA or pachydermoperiostosis is characterized by 
pachyderma, digital clubbing and periostosis (1, 2). It 
has an insidious onset, usually beginning in adolescence 
and presents with progressively worsening joint pain, 
enlargement of the extremities and coarsening facial 
features. The current case exemplifies this classical 
presentation and also the issue of being potentially 
mistaken for acromegaly. The patient was initially seen 
in a regional clinic and the presentation of facial changes 
and enlarged extremities led to his referral to exclude 
acromegaly. However, acromegaly was readily excluded 
by hormonal testing, whereas the presence of clubbing 
without underlying pulmonary, hepatic or malignant 
disease in a young individual pointed strongly to 
PHOA. This was supported by the radiological findings, 
with evidence of subperiosteal new bone formation, 
cortical thickening, epiphyseal widening and joint space 
narrowing.
PHOA is a rare disorder that was first described by 
Friedreich in the Hafner brothers in 1868 (3). In total, 
only a few hundred cases of primary hypertrophic 
osteoarthropathy have been reported in the literature 
(1, 2). The presentation can vary from the complete 
clinical picture seen in the current case to other forms 
affecting only the skeleton or the skin. After onset and 
worsening of clinical signs during adolescence and young 
adulthood, the clinical features of the disease tend to 
stabilize.
Most patients with this disease have autosomal 
recessive inheritance of inactivating mutations in either 
the HPGD or the SLCO2A1 gene (4, 5). The current case 
had a homozygous frameshift and early truncating 
mutation of the SLCO2A1 gene that has not been reported 
previously. This gene encodes a prostaglandin transporter 
protein, and patients with such mutations have increased 
levels of prostaglandin E2, which is in keeping with the 
proposed etiology of PHOA as a prostaglandin metabolism 
disorder. A recent overview of SLCO2A1 mutations in 
primary hypertrophic osteoarthropathy kindreds reported 
that less than 50 mutations have been identified in the 
clinical setting to date (6). Despite the genetic features in 
the current case, no other affected family members were 
identified.
The skeletal features in the current case were typical 
of those seen in the disease showing, subperiosteal new 
bone formation, cortical thickening and narrowing of 
joint spaces. Resorption of bone of the distal phalanges 
(acro-osteolysis) and ossification of inter-osseous 
membranes and ligaments can also be seen. Management 
is based on reduction of inflammation via non-steroidal 
anti-inflammatory drugs and bisphosphonates, whereas 
cosmesis can be improved with plastic surgery to remove 
excessive skin folds on the forehead and scalp and to 
address blepharoptosis, as is envisaged in the current 
case (7).
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